Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07296328 · ClinicalTrials.gov registry record · Phase 2
Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter
A Phase 2 study, sponsored by NYU Langone Health.
- Not yet
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT07296328 is a Phase 2 study that has not yet begun recruiting, run by NYU Langone Health. The registered enrollment target is 25 participants.
The verdict
NCT07296328, a Phase 2 study, has not yet begun recruiting, sponsored by NYU Langone Health.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
This Phase 2a clinical trial is an open-label, single-group, within-subjects pilot study designed to evaluate the safety, feasibility, and preliminary efficacy of psilocybin as a therapeutic intervention for adults with developmental stuttering. This pilot study will assess whether further research to explore the potential benefits of psilocybin-assisted therapy for improving clinical outcomes in individuals who stutter, is warranted. The aims of this study include: * Aim 1: Assess the safety and feasibility of psilocybin as a therapeutic agent for stuttering. * Aim 2: Evaluate the effects of psilocybin on objective and subjective measures of stuttering severity, struggle, and well-being. * Aim 3: Explore the therapeutic neural mechanisms of psilocybin in stuttering.
Interventions
- DRUG Psilocybin
- BEHAVIORAL Speech therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2026-01-15 |
| Est. Completion | 2027-04-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07296328
The ClinicalTrials.gov registry entry for NCT07296328 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Psilocybin is the first listed.
NCT07296328 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07296328 about?
NCT07296328 is a clinical study titled "Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter". This Phase 2a clinical trial is an open-label, single-group, within-subjects pilot study designed to evaluate the safety, feasibility, and preliminary efficacy of psilocybin as a therapeutic intervention for adults with developmental stuttering. This pilot study will assess whether further research ...
What is the current status of trial NCT07296328?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2026-01-15. Estimated completion is 2027-04-01.
What interventions are being tested in trial NCT07296328?
The interventions under investigation include: Psilocybin (DRUG), Speech therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT07296328?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.